首页   ·   人员   ·   固定科研人员(按首字母拼音顺序)   ·   正文

人员

  • 简要介绍:Craig Anderson is a Fellow of the Australian Academy of Health and Medical Sciences (elected in 2015). He has been serving as the head of the Brain Health program at The George Institute for Global Health since 2005, and as Professor of Neurology and Epidemiology in the Faculty of Medicine at the University of New South Wales since 2017. From 2022 to 2024, he was Vice-President of the World Stroke Organization. Additionally, he is currently Editor-in-Chief of Cerebrovascular Diseases and Associated Editor-in-Chief of the International Journal of Stroke. Craig has been appointed as a Distinguished Professor and Director of the new Center for International Clinical Trial and Translational Medicine (CCTM) in the Institute of Science and Technology for Brain-inspired Intelligence (ISTBI) at Fudan University. Craig is a pioneering figure in the field of stroke, particularly around blood pressure management for the prevention and acute treatment. He is recognized internationally as an authority on the causes, treatments, and management of stroke and other aspects of cardiovascular diseases. For over two decades, he has been leading a unique research program that combines clinical medicine with public health, collaborating with multidisciplinary teams across various countries, with a focus on middle- and low-income areas. He has initiated a worldwide research initiative comprised of international randomized controlled trials (RCTs) and population-based or registry studies, producing high-quality, patient-focused results that are broadly applicable in a variety of healthcare contexts. His research on early intensive blood pressure lowering in acute intracerebral hemorrhage (INTERACT and INTERACT2) has changed global clinical guidelines. The combined management study of intracerebral hemorrhage, known as INTERACT3, is the largest study in its field to date and marks the first time in history to produce definitive positive results. These findings provide the highest level of evidence to support the revision of clinical guidelines and changes in clinical practice. As of now, he has led numerous international, multicenter clinical studies on a large scale and has published over 700 papers, with more than 10 as the corresponding author in esteemed journals such as The New England Journal of Medicine (NEJM) and The Lancet. His current H-index is 107, and in 2020, he was recognized as one of the top 2% of scientists globally by Stanford University.
  • 代表成果:

    Anderson CS; INTERACT4 investigators; INTERACT4 Investigators. Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke. N Engl J Med. 2024 May 30;390(20):1862-1872.

    Anderson CS; INTERACT3 Investigators. The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial. Lancet. 2023 Jul 1;402(10395):27-40.

    Anderson CS; ENCHANTED2/MT Investigators. Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial. Lancet. 2022 Nov 5;400(10363):1585-1596.

    Anderson CS. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international randomised, open-label, blinded-endpoint phase 3 trial. Lancet 2019; 393(10174):877-888.

    Anderson CS; HeadPoST Investigators and Coordinators. Cluster-randomised, crossover trial of head positioning in acute stroke. New England Journal of Medicine. 2017;376 (25):2437-2447.

    Anderson CS; SAVE Investigators and Coordinators. CPAP for prevention of cardiovascular events in obstructive sleep apnoea. New England Journal of Medicine 2016; 375(10): 919-931.

    Anderson CS; ENCHANTED Investigators and Coordinators. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. New England Journal of Medicine 2016; 374(24): 2313-2323.

    Anderson CS; INTERACT2 Investigators. Rapid blood pressure lowering in acute intracerebral haemorrhage. New England Journal of Medicine 2013; 368(25):2355-65.